Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | HRH2 | P25021 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4089544 | 1.00 | HRH3 (0.40) | HRH3HRH2HRH1MAOB | |
| Iodide SCHEMBL5786537 | 0.96 | HRH3 (0.41) | HRH3HRH2HRH1MAOB | |
| SCHEMBL10469227 | 0.93 | HRH3 (0.39) | HRH3HRH2HRH1MAOB | |
| SCHEMBL5723633 | 0.91 | HRH3 (0.37) | HRH3HRH2HRH1 | |
| SCHEMBL24114570 | 0.91 | HRH3 (0.37) | HRH3HRH2HRH1 | |
| SCHEMBL4079655 | 0.86 | LTA4H (0.38) | HRH3HRH2HRH1MAOB | |
| SCHEMBL8237729 | 0.86 | LTA4H (0.38) | HRH3HRH2HRH1MAOB | |
| SCHEMBL4088693 | 0.86 | LTA4H (0.38) | HRH3HRH2HRH1MAOB | |
| SCHEMBL23828674 | 0.85 | HRH3 (0.44) | HRH3HRH2HRH1MAOB | |
| SCHEMBL25959399 | 0.80 | CASP3 (0.35) | HRH3HRH2HRH1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2065383-A1 | Indazole compounds and methods of use thereof as protein kinase inhibitors | Signal Pharmaceuticals, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | BHAGWAT SHRIPAD S | 2009-04-16 | — | — | US | disclosed |
| US-7504416-B2 | 4-substituted quinolines as antitumor agents | ASTRAZENECA AB (SE) | 2009-03-17 | — | — | US | disclosed |
| US-20080027054-A1 | 4-Substituted quinolines as antitumor agents | ASTRAZENECA AB | 2008-01-31 | — | — | US | disclosed |
| US-7253184-B2 | 4-Substituted quinolines as antitumor agents | ASTRAZENECA AB (SE) | 2007-08-07 | — | — | US | disclosed |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | BHAGWAT SHRIPAD S | 2006-01-05 | — | — | US | disclosed |
| US-20050101630-A1 | 4-Substituted quinolines as antitumor agents | ASTRAZENECA AB (SE) | 2005-05-12 | — | — | US | disclosed |
| EP-1337513-A1 | 4-SUBSTITUTED QUINOLINES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2003-08-27 | — | — | EP | disclosed |
| WO-2002036570-A1 | 4-SUBSTITUTED QUINOLINES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2002-05-10 | — | — | WO | disclosed |
| US-4452745-A | ANTIARRHYTHMIA AGENTS | ELI LILLY AND COMPANY (US) | 1984-06-05 | — | — | US | disclosed |
| EP-0018076-B1 | 9-AMINOALKYLFLUORENES, PROCESS THEREFOR AND ANTIARRHYTHMIC FORMULATIONS THEREOF | ELI LILLY AND COMPANY (US) | 1983-09-21 | — | — | EP | disclosed |
| US-4382093-A | 9-Aminoalkylfluorenes | ELI LILLY AND COMPANY (US) | 1983-05-03 | — | — | US | disclosed |
| US-4277495-A | FLUORENE 9-AMINOALKYL-9-CARBOXYLIC ACIDS OR ESTERS | ELI LILLY AND COMPANY (US) | 1981-07-07 | — | — | US | disclosed |
| EP-0018076-A1 | 9-Aminoalkylfluorenes, process therefor and antiarrhythmic formulations thereof | ELI LILLY AND COMPANY (US) | 1980-10-29 | — | — | EP | disclosed |
| US-4112103-A | Antiarrhythmic (+,-)-cis-α-[3-(2,6-dimethyl-1-piperidinyl)propyl]-α-phenyl-2-pyridinemethanols | PARKE, DAVIS & COMPANY (US) | 1978-09-05 | — | — | US | disclosed |
| US-4031101-A | ANTIARRHYTHMIA AGENT | PARKE, DAVIS & COMPANY (US) | 1977-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027054-A1 | 4-Substituted quinolines as antitumor agents | CCNY, TPD52L2, H1-10 | HRH3 345/4885HRH2 740/4885HRH1 1027/4885 |
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | WNT3, WNT3A, WNK3 | HRH3 2504/4885HRH2 3624/4885HRH1 3031/4885 |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | WNT3, WNT3A, WNK3 | HRH3 2769/4885HRH2 3827/4885HRH1 3325/4885 |
| US-20050101630-A1 | 4-Substituted quinolines as antitumor agents | NQO2, TPD52L2, MLX | HRH3 464/4885HRH2 807/4885HRH1 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.